Abstract: An optimized protein-free tripartite vaccine that protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram-positive bacteria, Gram-negative bacteria, and fungi.
Type:
Grant
Filed:
June 22, 2023
Date of Patent:
April 16, 2024
Assignee:
UNIVERSITY OF SOUTHERN CALIFORNIA
Inventors:
Brad Spellberg, Travis Nielsen, Brian Luna, Jun Yan
Abstract: Disclosed herein is a process for producing a postbiotic extract, which includes providing a first material having a first isoelectric point ranging from pH 1 to pH 6 and a second material having a second isoelectric point ranging from pH 4 to pH 8, admixing the first material and a probiotic microorganism with water having a pH greater than the second isoelectric point, so as to form a mixture, adding the second material into the mixture and then adjusting a pH of the second material-added mixture to between the first and second isoelectric points so that a precipitate is formed, and subjecting the precipitate to a cell wall isolation treatment to obtain the postbiotic extract. Use of the postbiotic extract is also disclosed.
Abstract: Disclosed herein is a process for producing a postbiotic extract, which includes providing a first material having a first isoelectric point ranging from pH 1 to pH 6 and a second material having a second isoelectric point ranging from pH 4 to pH 8, admixing the first material and a probiotic microorganism with water having a pH greater than the second isoelectric point, so as to form a mixture, adding the second material into the mixture and then adjusting a pH of the second material-added mixture to between the first and second isoelectric points so that a precipitate is formed, and subjecting the precipitate to a cell wall isolation treatment to obtain the postbiotic extract. Use of the postbiotic extract is also disclosed.
Abstract: The present invention relates to immunogens directed against lung cancer associated proliferative peptides and growth factors and its uses thereof in conjunction with chemotherapeutics in the early and advanced treatment of various malignant diseases, especially including lung cancers, both small cell lung carcinomas (SCLC), non-small cell lung (NSCLC) cancers and neuroendocrine-type cancers.
Abstract: Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
Type:
Grant
Filed:
October 8, 2020
Date of Patent:
February 27, 2024
Assignee:
INIMMUNE CORPORATION
Inventors:
Paul L. Bollyky, William Parks, Patrick Secor
Abstract: Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.
Abstract: The present invention relates to a microorganism which can act as a biomarker of alcoholic fatty liver disease, and relates to a pharmaceutical composition for preventing or treating alcoholic fatty liver disease, a food composition for preventing or improving alcoholic fatty liver disease, or a probiotics composition for preventing or improving alcoholic fatty liver disease, comprising the strain as an active ingredient.
Type:
Grant
Filed:
October 27, 2022
Date of Patent:
February 20, 2024
Assignee:
KOBIOLABS, INC.
Inventors:
Gwangpyo Ko, Boram Seo, Woon Ki Kim, Kyungchan Jeon
Abstract: Methods of treating or preventing stress, anxiety, or postoperative cognitive dysfunction. Also provided are methods of improving resilience in a subject by administering a therapeutically effective amount of isolated mycobacterium.
Type:
Grant
Filed:
August 22, 2022
Date of Patent:
February 20, 2024
Assignee:
The Regents of the University of Colorado, a body corporate
Inventors:
Christopher A. Lowry, Matthew G. Frank, Laura Fonken, Steven F. Maier
Abstract: This disclosure relates to methods of using beneficial bacterial such as, a Lactococcus lactis strain, to manage, treat, or prevent obesity, fatty liver disease, harmful ionizing radiation, and other conditions or aliments. In certain embodiments, the subject is at risk or, susceptible to, exhibiting symptoms of, or diagnosed with a disease or conditions disclosed herein. In certain embodiments, methods comprise administering an effective amount of a Lactococcus lactis strain to a subject in need thereof. In certain embodiments, the Lactococcus lactis strain is Lactococcus lactis subsp. cremoris ATCC® 19257 or a mutant thereof.
Abstract: Adjuvants comprising chitosan cross-linked with an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used in methods to vaccinate animals against the source of the antigen or to enhance the immune response in a subject.
Type:
Grant
Filed:
September 15, 2020
Date of Patent:
January 30, 2024
Assignee:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Inventors:
Billy M. Hargis, Neil R. Pumford, Marion Morgan, Srichaitanya Shivaramaiah, Guillermo Tellez-Isaias, Amanda Wolfenden
Abstract: Provided herein are methods and compositions related to treating or preventing seizures. In some aspects, provided herein are methods of treating or preventing seizures in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.
Type:
Grant
Filed:
September 27, 2021
Date of Patent:
January 30, 2024
Assignee:
The Regents of the University of California
Inventors:
Elaine Y. Hsiao, Jessica Yano, Helen E. Vuong, Christine Olson
Abstract: Provided herein are isolated proteins isolatable from a Klebsiella spp. Also provided are compositions that include one or more of the proteins, and methods for making and methods for using the proteins.
Type:
Grant
Filed:
April 9, 2021
Date of Patent:
January 16, 2024
Assignee:
Epitopix, LLC
Inventors:
Douglas T. Burkhardt, Daryll Emery, Darren Straub
Abstract: To identify a microorganism causing the development of primary sclerosing cholangitis associated with ulcerative colitis. A Klebsiella pneumoniae strain inducing inflammation in the liver.
Abstract: The present invention provides Shiga toxin A Subunit derived polypeptides, scaffolds, and cell-targeting molecules comprising amino acid substitutions which equip the molecules with site-specific positions (and often unique amino acid residues in the molecule) for linking other molecules while retaining Shiga toxin function(s), such as, e.g., efficient intracellular routing and/or potent cytotoxicity. The present invention also provides cell-targeting molecules, and/or components thereof, which comprise site-specific positions for linking other molecules, such as, e.g., agents that alters a property of the cell-targeting molecule or a cargo for delivery. Certain molecules comprising a polypeptide of the present invention exhibit reduced immunogenicity and/or are well-tolerated by mammals. The cell-targeting molecules of the present invention, and compositions thereof, have uses, e.g.
Abstract: To identify a microorganism causing the development of primary sclerosing cholangitis associated with ulcerative colitis. A Klebsiella pneumoniae strain inducing inflammation in the liver.
Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.
Type:
Grant
Filed:
October 19, 2016
Date of Patent:
December 19, 2023
Assignee:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Elisabeth Marie Monique Bertaud, Ralph Leon Biemans, Nicolas Jean Benoit Moniotte, Laurent Bernard Jean Strodiot
Abstract: A strain of Bifidobacterium longum APC 1472 is described. The strain has weight lowering effects in-vivo, achieved through inducing satiety via decreased internalisation of the Ghrelin receptor, and therefore, decreased constitutive activity. Moreover, the strain also showed a trend towards decreased ghrelin receptor hypothalamic expression in HFD-fed mice when compared with vehicle control group. The strain also improves glucose tolerance and decreased insulin plasma levels in mice, indicating the strain in the prevention and/or treatment of Type II diabetes, especially in obese individuals.
Type:
Grant
Filed:
August 27, 2018
Date of Patent:
December 5, 2023
Assignees:
UNIVERSITY COLLEGE CORK—NATIONAL UNIVERSITY OF IRELAND, CORK, AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY (TEAGASC)
Inventors:
John Cryan, Ted Dinan, Catherine Stanton, Harriet Schellekens, Cristina Torres, Bernard Roy
Abstract: Variant factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of Neisseria meningitidis, compositions comprising such proteins, and methods of use of such proteins, are provided.
Type:
Grant
Filed:
October 7, 2020
Date of Patent:
December 5, 2023
Assignee:
Children's Hospital & Research Center at Oakland